CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory (R/R), measurable residual disease (MRD) positive acute myeloid leukemia...
Phase 1
Nashville, Tennessee, United States and 2 other locations
in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The main study has completed enrollment.In Sub-studies 1 and 2...
Phase 1, Phase 2
Nashville, Tennessee, United States and 55 other locations
in treating pediatric and young adult patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage (ALAL) that...
Phase 1
Nashville, Tennessee, United States and 7 other locations
(bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be enrolled into 3 following cohorts: tre...
Phase 3
Nashville, Tennessee, United States and 108 other locations
GDX012 is a novel cell therapy developed for the treatment of certain types of cancer, including Acute Myeloid Leukemia (AML). The main aims...
Phase 1, Phase 2
Nashville, Tennessee, United States and 13 other locations
Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomized to receive gilteritinib ...
Phase 2
Nashville, Tennessee, United States and 43 other locations
chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (rux...
Phase 2
Nashville, Tennessee, United States and 110 other locations
This first-in-human study will evaluate RVU120 (SEL120), a novel small molecule CDK8/19 inhibitor, in patients with Acute Myeloid Leukemia (...
Phase 1
Nashville, Tennessee, United States and 9 other locations
participants with previously treated chronic phase - chronic myeloid leukemia (CP-CML).The study has two parts: Part 1 of the trial (Dose Es...
Phase 1
Nashville, Tennessee, United States and 39 other locations
This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL...
Phase 1, Phase 2
Nashville, Tennessee, United States and 9 other locations
Clinical trials
Research sites
Resources
Legal